Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus

D. Pulanić, A. Bátorová, I. Bodó, L. Červinek, I. Ionita, T. Lissitchkov, A. Melikyan, M. Podolak-Dawidziak

. 2023 ; 102 (4) : 715-727. [pub] 20230224

Language English Country Germany

Document type Systematic Review, Journal Article

Persistent link   https://www.medvik.cz/link/bmc23003646

There are currently three thrombopoietin receptor agonists (TPO-RAs) approved in Europe for treating patients with immune thrombocytopenia (ITP): romiplostim (Nplate®), eltrombopag (Revolade®), and avatrombopag (Doptelet®). However, comparative clinical data between these TPO-RAs are limited. Therefore, the purpose of this study was to perform a literature review and seek expert opinion on the relevance and strength of the evidence concerning the use of TPO-RAs in adults with ITP. A systematic search was conducted in PubMed and Embase within the last 10 years and until June 20, 2022. A total of 478 unique articles were retrieved and reviewed for relevance. The expert consensus panel comprised ITP senior hematologists from eight countries across Central Europe. The modified Delphi method, consisting of two survey rounds, a teleconference and email correspondence, was used to reach consensus. Forty articles met the relevancy criteria and are included as supporting evidence, including five meta-analyses analyzing all three European-licensed TPO-RAs and comprising a total of 31 unique randomized controlled trials (RCTs). Consensus was reached on seven statements for the second-line use of TPO-RAs in the management of adult ITP patients. In addition, the expert panel discussed TPO-RA treatment in chronic ITP patients with mild/moderate COVID-19 and ITP patients in the first-line setting but failed to reach consensus. This work will facilitate informed decision-making for healthcare providers treating adult ITP patients with TPO-RAs. However, further studies are needed on the use of TPO-RAs in the first-line setting and specific patient populations.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003646
003      
CZ-PrNML
005      
20230425140757.0
007      
ta
008      
230418s2023 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-023-05114-8 $2 doi
035    __
$a (PubMed)36826482
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Pulanić, Dražen $u Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, University of Zagreb, School of Medicine, Kispaticeva 12, 10 000, Zagreb, Croatia. dpulanic@yahoo.com $1 https://orcid.org/0000000211778921
245    10
$a Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus / $c D. Pulanić, A. Bátorová, I. Bodó, L. Červinek, I. Ionita, T. Lissitchkov, A. Melikyan, M. Podolak-Dawidziak
520    9_
$a There are currently three thrombopoietin receptor agonists (TPO-RAs) approved in Europe for treating patients with immune thrombocytopenia (ITP): romiplostim (Nplate®), eltrombopag (Revolade®), and avatrombopag (Doptelet®). However, comparative clinical data between these TPO-RAs are limited. Therefore, the purpose of this study was to perform a literature review and seek expert opinion on the relevance and strength of the evidence concerning the use of TPO-RAs in adults with ITP. A systematic search was conducted in PubMed and Embase within the last 10 years and until June 20, 2022. A total of 478 unique articles were retrieved and reviewed for relevance. The expert consensus panel comprised ITP senior hematologists from eight countries across Central Europe. The modified Delphi method, consisting of two survey rounds, a teleconference and email correspondence, was used to reach consensus. Forty articles met the relevancy criteria and are included as supporting evidence, including five meta-analyses analyzing all three European-licensed TPO-RAs and comprising a total of 31 unique randomized controlled trials (RCTs). Consensus was reached on seven statements for the second-line use of TPO-RAs in the management of adult ITP patients. In addition, the expert panel discussed TPO-RA treatment in chronic ITP patients with mild/moderate COVID-19 and ITP patients in the first-line setting but failed to reach consensus. This work will facilitate informed decision-making for healthcare providers treating adult ITP patients with TPO-RAs. However, further studies are needed on the use of TPO-RAs in the first-line setting and specific patient populations.
650    _2
$a lidé $7 D006801
650    _2
$a dospělí $7 D000328
650    12
$a idiopatická trombocytopenická purpura $x farmakoterapie $x chemicky indukované $7 D016553
650    _2
$a receptory thrombopoetinu $x agonisté $7 D053628
650    _2
$a konsensus $7 D032921
650    12
$a COVID-19 $7 D000086382
650    12
$a trombocytopenie $x chemicky indukované $7 D013921
650    _2
$a thrombopoetin $x terapeutické užití $7 D013926
650    _2
$a receptory Fc $x terapeutické užití $7 D011961
650    _2
$a benzoáty $x terapeutické užití $7 D001565
650    _2
$a hydraziny $x terapeutické užití $7 D006834
650    _2
$a rekombinantní fúzní proteiny $x terapeutické užití $7 D011993
655    _2
$a systematický přehled $7 D000078182
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bátorová, Angelika $u Department of Hematology and Transfusion Medicine, National Hemophilia Center, Faculty of Medicine of Comenius University and University Hospital Bratislava, Bratislava, Slovakia $1 https://orcid.org/0000000305674250
700    1_
$a Bodó, Imre $u 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary $1 https://orcid.org/0000000341708577
700    1_
$a Červinek, Libor $u Faculty Hospital Brno, Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic
700    1_
$a Ionita, Ioana $u Department of Internal Medicine, Victor Babes University of Medicine and Pharmacy, HematologyTimisoara, Romania $1 https://orcid.org/0000000306814198
700    1_
$a Lissitchkov, Toshko $u Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria $1 https://orcid.org/0000000322388598
700    1_
$a Melikyan, Anahit $u Department of Standardization of Treatment Methods, National Research Center for Hematology Russian Federation, Moscow, Russia
700    1_
$a Podolak-Dawidziak, Maria $u Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland $1 https://orcid.org/0000000339873100
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 102, č. 4 (2023), s. 715-727
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36826482 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140754 $b ABA008
999    __
$a ok $b bmc $g 1924366 $s 1189855
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 102 $c 4 $d 715-727 $e 20230224 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options